| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Inhibikase Therapeutics, Inc. | President & Head of R&D | Common Stock | 1.01M | $1.7M | $1.68 | Feb 21, 2025 | Direct |
| Zura Bio Ltd | CMO & Head of R&D | Class A Ordinary Shares | 162K | $648K | $4.00 | May 18, 2023 | Direct |
| Inhibikase Therapeutics, Inc. | President & Head of R&D | Stock Option (Right to Buy) | 1.1M | Feb 21, 2025 | Direct | ||
| Pulmatrix, Inc. | Director | Stock Option (Right to Buy) | 1.7K | Jan 26, 2023 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| IKT | Inhibikase Therapeutics, Inc. | Feb 21, 2025 | 0 | $0 | 3/A | Aug 28, 2025 | President & Head of R&D |
| IKT | Inhibikase Therapeutics, Inc. | Feb 21, 2025 | 1 | $0 | 4/A | Jul 2, 2025 | President & Head of R&D |
| ZURA | Zura Bio Ltd | May 18, 2023 | 1 | $0 | 4 | May 22, 2023 | CMO & Head of R&D |
| ZURA | Zura Bio Ltd | Mar 20, 2023 | 0 | $0 | 3 | Mar 21, 2023 | EVP and CMO |
| PULM | Pulmatrix, Inc. | Jan 26, 2023 | 1 | $0 | 4 | Jan 30, 2023 | Director |
| PULM | Pulmatrix, Inc. | Jan 27, 2022 | 1 | $0 | 4 | Jan 31, 2022 | Director |